Plataforma de Cribado de Fármacos y Farmacogenómica
REACT-EU PROJECT
CONVENIO DE COLABORACIÓN ENTRE A AXENCIA GALEGA DE INNOVACIÓN E A UNIVERSIDADE DE SANTIAGO DE COMPOSTELA PARA REGULAR AS CONDICIÓNS DA AXUDA DESTINADA Á ACTUALIZACIÓN E AMPLIACIÓN DA PLATAFORMA INNOPHARMA DA USC
Click para más Info
Las infraestructuras de alta capacidad de INNOPHARMA ofrecen un conjunto de servicios que cobren todas las etapas del proceso de descubrimiento temprano de fármacos, desde la identificación de dianas hasta la evaluación preliminar de seguridad y toxicidad. La plataforma está disponible tanto para servicios a la carta como para proyectos complementarios de colaboración en el descubrimiento de fármacos.
-
Drug discovery program design
- Candidate Target Profile definition
- Feasibility/druggability assessment
- Screening cascade design
- Identification of hits, leads and candidates
Assay development, miniaturization, and automation
- Target-based assays
- Phenotypic assays
- Deconvolution assays
- Custom assays
De-risking programs
- Drug discovery programs up to proof of concept stage
Chemical compound libraries
- Compounds selected in silico based on biological and structural diversity
- Proprietary compounds
- Drug repurposing libraries
- Target-focused sub-libraries
Pharmacogenomics studies
- Biomarkers identification
- Identification of novel therapeutic targets
In vitro preliminary ADME-Tox and safety
- Cytochrome P450 induction and inhibition
- Cytotoxicity
- hERG channel
- Chemical, microsomal and plasma stability
- Plasma protein binding
- Permeability assay
- P-glycoprotein
- Genotoxicity
Customized assay development
- Target engagement
- Phenotypic assays
- Deconvolution assays
-
From INNOPHARMA we are constantly developing new tests and implementing new technologies, so if you have any interest in any test or technology not included in this list, please contact us
COVID-19
IN VITRO ASSAYS
ACE2 activity
TMPRSS2 activity
Furin activityTARGET-BASED
GPCRs
Radioligand Assays Adenosine A1
A2A
A2B
A3Dopamine D1
D2
D3
D4
D5Histamine H1
H2
H3
Adrenergic:α1
α2
α2C
β1
β2
β3Serotonin 5-HT1A 5-HT1B 5-HT1D
5-HT2A 5-HT2B 5- HT2C
5-HT5A 5-HT6 5-HT7Cannabinoid: CB1
CB2Muscarinic: M1
M2
M3
M4
M5Second Messengers Arachidonic acid metabolism Nitric oxide synthase Inositol phosphate Calcium mobilization Isolated Organ Assays Adenosine: A1 A2A A2B
Adrenergic: α1 α2 β1
Histamine: H1 H2
Muscarinic: M1 M2 M3
Serotonin: 5-HT2A 5-HT2B 5-HT3 5-HT4Beta-Arrestin Translocation - BRET Mu-opioid CX3CR1 TRANSPORTERS
Radioligand Assays Dopamine (DAT) Noradrenaline (NAT) Serotonin (5-HTT) NUCLEAR RECEPTORS
Radioligand Assays Estrogen receptors (ER)
Androgen receptor (AR)
Progesterone receptor (PR)
Glucocorticoid receptor (GR)
Peroxisome proliferator-activated receptors (PPAR)
Prostanoid receptors (PR)Functional assays Androgen receptor (AR)
Glucocorticoid receptor (GR)ENZYMES
Kinase profiling > 250 functional assays Phosphodiesterases: 15 activity assays Phosphatases Beta-secretase Acetylcholinesterase Monoamine oxidases: MAO-A, MAO-B Epigenetic enzymes ION CHANNELS
Voltage-gated Calcium
Potasium
Sodium
hERGMembrane ligand-gated NMDA
GABAA
5-HT3PHENOTYPIC ASSAYS
CELL VIABILITY AND CYTOTOXICITY IN 20+ HUMAN CELL LINES
MORPHOLOGICAL PROFILING BY HIGH-CONTENT IMAGING (CELL PAINTING)
PHENOTYPIC PROFILING BY LABEL-FREE DYNAMIC MASS REDISTRIBUTION-BASED ASSAYS
TARGET-DECONVOLUTION STRATEGIES
IN VITRO TRANSLATIONAL DISEASE-RELATED ASSAYS
Neurological and neurodegenerative diseases Neurite outgrowth
α-synuclein aggregationMetabolic- disease Adipocyte assay PRELIMINARY ADME-Tox AND SAFETY ASSAYS
CITOTOXICITY
Cell Lines Cancer cell lines Human ovarian carcinoma: A2780, A2780cis, NCI-ADR/RES
Human cervix carcinoma: HeLa 229
Human breast carcinoma: MCF-7, T47D, MDA-MB-231, Hs578T
Human lung carcinoma: NCI-H460, A549
Human glioblastoma: SF268
Human colon carcinoma: CACO-2, HT-29, HCT116
Human liver carcinoma: Hep-G2
Human neuroblastoma: SH-SY5Y
Human acute myeloid leukemia: HL-60
Human pancreatic carcinoma: CFPAC-1
Human prostate carcinoma: LNCaP, PC3
Human osteosarcoma: U2OSOther cell lines Human lung fibroblasts: MRC-5
Porcine kidney cell line: LLC-PK1Cell Viability Technologies Crystal violet MTT reduction Sulforhodamine B ATP production CYTOCHROME INDUCTION AND INHIBITION
Recombinant P450 (1A2, 2C9, 2C19, 2D6, 3A4) hERG
CHANNEL PERMEABILITY ASSAYS
CACO-2 (6-well, 24-well and 96-well formats) P-GLYCOPROTEIN SUBSTRATE
SOLUBILITY ASSAYS
Aqueous solubility (pH-dependent) MICROSOMAL STABILITY
In several species PLASMA PROTEIN BINDING
In several species PLASMA STABILITY
In several species GENOTOXICITY
Micronucleus assay CUSTOMIZED ASSAYS
AD-HOC ASSAY DEVELOPMENT AND SCREENING
Target engagement Phenotypic assays Target deconvolution strategies -
The Innopharma Platform has state-of the art equipment for carrying out assay development projects and screening campaigns with different technological approaches
- Radioactivity (Filtration and SPA)
- Absorbance
- Fluorescence intensity and polarization
- Luminescence
- FRET and Homogeneous Time-Resolved Fluorescence
- BRET
- Alphascreen
- Fluorescence Lifetime Imaging
- Automated patch-clamp
- Label free (Dynamic Mass Redistribution)
- Automated mobility shift (Lab on a chip)
- High Content Screening
- UPLC-MS/MS
- Genome wide and candidate gene association studies
- Next Generation Sequencing
-
Plataforma de Cribado de Fármacos y Farmacogenómica INNOPHARMA
- CIMUS
- Avenida de Barcelona, s/n, 15782Santiago de Compostela
- 881 815 459
- innopharma@usc.es